Clyra Medical, a subsidiary of BioLargo, Inc., presented the results of its ViaCLYR wound‑irrigation solution at the Boswick Symposium in Maui, Hawaii, held from January 24 to 30, 2026. The presentation was delivered by Dr. Marcus Gitterle, Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy at Christus Santa Rosa Hospital System and co‑founder of Wound Centrix LLC.
The study included 36 cases across four wound‑care clinics over a four‑month period. Results showed rapid wound transformation, enhanced healing, and strong antimicrobial performance across multiple wound types, underscoring the effectiveness of Clyrasept, the proprietary technology that powers ViaCLYR.
These findings represent a key milestone for Clyra Medical’s product pipeline, supporting the company’s planned commercial launch of ViaCLYR in 2026. The presentation demonstrates the solution’s clinical efficacy and safety, positioning the company to pursue regulatory submissions, attract potential partners or investors, and build confidence in the product’s market potential.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.